S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan

Allogene Therapeutics (ALLO) News Today

$4.94
+0.03 (+0.61%)
(As of 03/1/2024 ET)
SourceHeadline
marketbeat.com logoCaxton Associates LP Has $1.52 Million Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
marketbeat.com - February 28 at 3:48 PM
globenewswire.com logoAllogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
globenewswire.com - February 28 at 8:30 AM
MarketBeat logoJPMorgan Chase & Co. Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $8.00
americanbankingnews.com - February 28 at 5:00 AM
marketbeat.com logoPrimecap Management Co. CA Lowers Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
marketbeat.com - February 26 at 8:56 AM
ca.finance.yahoo.com logoALGS Apr 2024 2.500 call
ca.finance.yahoo.com - February 25 at 10:19 AM
marketbeat.com logoAllogene Therapeutics (ALLO) Set to Announce Quarterly Earnings on Monday
marketbeat.com - February 25 at 7:32 AM
MarketBeat logoAllogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Recommendation of "Moderate Buy" from Analysts
americanbankingnews.com - February 22 at 1:36 AM
finance.yahoo.com logoAllogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
finance.yahoo.com - February 16 at 8:59 AM
globenewswire.com logoAllogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
globenewswire.com - February 16 at 8:30 AM
marketbeat.com logoBarclays PLC Boosts Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
marketbeat.com - February 14 at 4:36 AM
marketbeat.com logoAllogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Significant Decline in Short Interest
marketbeat.com - February 13 at 8:41 AM
marketbeat.com logoQ1 2024 EPS Estimates for Allogene Therapeutics, Inc. (NASDAQ:ALLO) Lifted by Zacks Research
marketbeat.com - February 8 at 7:30 AM
uk.investing.com logoAllogene Therapeutics Inc (ALLO)
uk.investing.com - January 30 at 2:23 PM
marketbeat.com logoAllogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Recommendation of "Moderate Buy" from Brokerages
marketbeat.com - January 28 at 2:52 AM
finanznachrichten.de logoDelveInsight Business Research, LLP: CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsight
finanznachrichten.de - January 23 at 5:27 PM
realmoney.thestreet.com logoAllogene Therapeutics price target lowered by $2 at H.C. Wainwright, here's why
realmoney.thestreet.com - January 19 at 12:47 PM
marketbeat.com logoAllogene Therapeutics (NASDAQ:ALLO) Shares Down 5% After Analyst Downgrade
marketbeat.com - January 19 at 12:32 PM
marketbeat.com logoAllogene Therapeutics (NASDAQ:ALLO) Price Target Cut to $10.00
marketbeat.com - January 19 at 8:15 AM
marketbeat.com logoQ1 2024 EPS Estimates for Allogene Therapeutics, Inc. Increased by Zacks Research (NASDAQ:ALLO)
marketbeat.com - January 15 at 1:57 AM
seekingalpha.com logoAllogene Therapeutics: A Promising Biotech With A Concerning Lag Time Ahead
seekingalpha.com - January 8 at 12:00 AM
msn.com logoJMP Securities Downgrades Allogene Therapeutics (ALLO)
msn.com - January 7 at 10:09 AM
msn.com logoAllogene drops on layoffs and pipeline reorganization (update)
msn.com - January 6 at 10:53 PM
msn.com logoGuggenheim Downgrades Allogene Therapeutics (ALLO)
msn.com - January 6 at 10:53 PM
msn.com logoAllogene cuts 22% of workforce amid blood cancer therapy pivot
msn.com - January 5 at 9:52 PM
in.investing.com logoAllogene Therapeutics shares plunge, company announces 22% workforce reduction
in.investing.com - January 5 at 4:51 PM
marketwatch.com logoAllogene Therapeutics Shares Fall on Strategy Shift, Job Cuts
marketwatch.com - January 5 at 4:51 PM
markets.businessinsider.com logoAllogene Therapeutics To Lay Off 22% Of Its Workforce; Stock Down
markets.businessinsider.com - January 5 at 4:51 PM
msn.com logoAllogene drops on plans for pipeline reorganization
msn.com - January 5 at 8:19 AM
marketbeat.com logoJMP Securities Reiterates Market Perform Rating for Allogene Therapeutics (NASDAQ:ALLO)
marketbeat.com - January 5 at 8:11 AM
marketbeat.com logoAllogene Therapeutics (NASDAQ:ALLO) Downgraded to Neutral at Guggenheim
marketbeat.com - January 5 at 8:11 AM
finance.yahoo.com logoAllogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 6:12 PM
marketbeat.com logoAllogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Up 5.3% in December
marketbeat.com - January 3 at 5:49 AM
msn.com logoAllogene Therapeutics, Mesoblast among healthcare movers
msn.com - December 22 at 12:42 PM
marketbeat.com logoAllogene Therapeutics, Inc. (NASDAQ:ALLO) Director Sells $50,328.00 in Stock
marketbeat.com - December 20 at 7:04 PM
markets.businessinsider.com logoBuy Rating on Allogene Therapeutics Backed by Promising Clinical Data and Strategic Advancements
markets.businessinsider.com - December 11 at 3:17 PM
finance.yahoo.com logoAllogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
finance.yahoo.com - December 9 at 12:45 PM
msn.com logoCitigroup Initiates Coverage of Allogene Therapeutics (ALLO) with Buy Recommendation
msn.com - December 9 at 7:44 AM
realmoney.thestreet.com logoAllogene Therapeutics initiated with bullish view at Citi, here's why
realmoney.thestreet.com - December 8 at 10:00 AM
benzinga.com logoAllogene Therapeutics Stock (NASDAQ:ALLO) Dividends: History, Yield and Dates
benzinga.com - November 24 at 1:00 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and LAVA Therapeutics (LVTX)
markets.businessinsider.com - November 22 at 6:40 PM
msn.com logoGain Therapeutics (GANX) Down 25% on Issue of New Common Stock
msn.com - November 22 at 1:40 PM
markets.businessinsider.com logoAllogene Therapeutics Gains Buy Rating: Strong Q3 Financials, Promising Clinical Trials and Catalysts Ahead
markets.businessinsider.com - November 16 at 10:03 AM
finance.yahoo.com logoAllogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know
finance.yahoo.com - November 10 at 2:42 PM
markets.businessinsider.com logoMaintaining Buy Rating on Allogene Therapeutics: Encouraging Financials, Pipeline, and Therapeutic Potential
markets.businessinsider.com - November 6 at 8:33 PM
markets.businessinsider.com logoHold Rating for Allogene Therapeutics Amid Clinical Trials Progress and Financial Concerns
markets.businessinsider.com - November 6 at 3:33 PM
markets.businessinsider.com logoPromising Clinical Trials and Innovative Strategies Bolster Buy Rating for Allogene Therapeutics: An Analysis by John Newman
markets.businessinsider.com - November 4 at 10:13 AM
finanznachrichten.de logoAllogene Therapeutics, Inc.: Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
finanznachrichten.de - November 3 at 10:24 PM
markets.businessinsider.com logoPromising Clinical Trials and Future Market Potential Drive Buy Rating for Allogene Therapeutics
markets.businessinsider.com - November 3 at 5:23 PM
msn.com logoAllogene shares rally 22% amid Q3 report, medical meeting presentations
msn.com - November 3 at 5:23 PM
finance.yahoo.com logoAllogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss
finance.yahoo.com - November 3 at 12:23 PM
Get Allogene Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.



ALLO Media Mentions By Week

ALLO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALLO
News Sentiment

0.29

0.64

Average
Medical
News Sentiment

ALLO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALLO Articles
This Week

9

3

ALLO Articles
Average Week

Get Allogene Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ALLO) was last updated on 3/3/2024 by MarketBeat.com Staff